Insider Selling: LifeStance Health Group (NASDAQ:LFST) COO Sells $519,845.20 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) COO Lisa Miller sold 47,912 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the transaction, the chief operating officer directly owned 281,289 shares of the company’s stock, valued at approximately $3,051,985.65. The trade was a 14.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

LifeStance Health Group Trading Up 1.6%

LFST opened at $12.42 on Friday. The stock has a 50-day moving average of $10.39 and a 200 day moving average of $8.22. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a 12 month low of $4.77 and a 12 month high of $12.76. The firm has a market cap of $4.82 billion, a P/E ratio of 95.55 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.01) earnings per share. As a group, research analysts forecast that LifeStance Health Group, Inc. will post 0.15 EPS for the current year.

Wall Street Analyst Weigh In

LFST has been the subject of a number of analyst reports. KeyCorp raised their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Canaccord Genuity Group boosted their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Wall Street Zen raised shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday. JPMorgan Chase & Co. raised their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday. Finally, BTIG Research lifted their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and an average price target of $12.12.

Institutional Trading of LifeStance Health Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC boosted its stake in shares of LifeStance Health Group by 19,952.6% during the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares during the period. KBC Group NV purchased a new position in LifeStance Health Group in the 1st quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its holdings in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after buying an additional 5,404 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after buying an additional 7,987 shares during the period. Finally, Assetmark Inc. boosted its position in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after buying an additional 1,367 shares during the period. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.